ZVRA - Zevra Therapeutics, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

ZVRA

ZEVRA THERAPEUTICS, INC.

NASDAQ

$11.56

▼ DOWN 2.41% (-0.28)

KEY STATISTICS

Market Cap$683.67 M

52w High$15.04

52w Low$7.16

Dividend Yield—

Frequency—

P/E12.30

Volume617.86K

Shares Out.59.12M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Neil F. McFarlane

COMPENSATION 2026

Salary$729,167

Stock Awards$874,125

Incentive Plan Pay$418,950

All Other Comp.$11,550

Total$3,782,042

ABOUT

SECTOR

Healthcare

WENT PUBLIC

April 16, 2015

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$35.00

Target Low$20.00

Target Median$24.00

Target Consensus$25.75

UPCOMING EARNINGS

DateNov 4, 2026

DayWednesday

Rev. Est.$37.08M

NOV

WED

SPLIT RECORD

DATE	TYPE	RATIO
2020-12-28	Reverse	1:16

PRICE

$11.56 ▼ DOWN 2.41% (−$0.28)

OVERLAYS

About Zevra Therapeutics, Inc.

https://zevra.com ↗

Zevra Therapeutics develops proprietary prodrugs using Ligand Activated Therapy to treat rare CNS diseases and disorders like ADHD, narcolepsy, and stimulant use disorder, with several candidates in clinical trials and FDA-approved products.

INDUSTRY

Biotechnology

A PRODUCT ZEVRA THERAPEUTICS, INC. IS KNOWN FOR

MIPLYFFA®

MIPLYFFA™ (arimoclomol) is the first FDA-approved treatment for Niemann-Pick disease type C, a rare neurodegenerative disorder, with a successful commercial launch exceeding expectations for Zevra Therapeutics.